Recomendaciones 2013 para el uso de la monitorización ambulatoria de la presión arterial para el diagnóstico de hipertensión en adultos, valoración de riesgo cardiovascular y obtención de objetivos terapéuticos (resumen). Recomendaciones conjuntas de la International Society for Chronobiology (ISC), American Association of Medical Chronobiology and Chronotherapeutics (AAMCC), Sociedad Española de Cronobiología Aplicada, Cronoterapia y Riesgo Vascular (SECAC), Sociedad Española de Arteriosclerosis (SEA) y Romanian Society of Internal Medicine (RSIM)

  1. Hermida Domínguez, Ramón Carmelo
  2. Smolensky, Michael H.
  3. Ayala García, Diana E.
  4. Portaluppi, Francesco
  5. Crespo, Juan J.
  6. Fabbian, Fabio
  7. Haus, Erhard
  8. Manfredini, Roberto
  9. Mojón Ojea, Artemio
  10. Moyá Álvarez, Ana
  11. Piñeiro Gómez-Durán, Luis
  12. Ríos Rey, María Teresa
  13. Otero González, Alfonso
  14. Balan, Horia
  15. Fernández Bernárdez, José Ramón
Revista:
Clínica e investigación en arteriosclerosis

ISSN: 0214-9168 1578-1879

Any de publicació: 2013

Volum: 25

Número: 2

Pàgines: 74-82

Tipus: Article

DOI: 10.1016/J.ARTERI.2013.03.002 PMID: 23849214 SCOPUS: 2-s2.0-84881368708 DIALNET GOOGLE SCHOLAR

Altres publicacions en: Clínica e investigación en arteriosclerosis

Objectius de Desenvolupament Sostenible

Resum

Correlation between systolic (SBP) and diastolic (DBP) blood pressure (BP) level and target organ damage, cardiovascular disease (CVD) risk, and long-term prognosis is much greater for ambulatory BP monitoring (ABPM) than daytime office measurements. The 2013 ABPM guidelines specified herein are based on ABPM patient outcomes studies and constitute a substantial revision of current knowledge. The asleep SBP mean and sleep-time relative SBP decline are the most significant predictors of CVD events, both individually as well as jointly when combined with other ABPM-derived prognostic markers. Thus, they should be preferably used to diagnose hypertension and assess CVD and other associated risks. Progressive decrease by therapeutic intervention in the asleep BP mean is the most significant predictor of CVD event-free interval. The 24 h BP mean is not recommended to diagnose hypertension because it disregards the more valuable clinical information pertaining to the features of the 24 h BP pattern. Persons with the same 24 h BP mean may display radically different 24 h BP patterns, ranging from extreme-dipper to riser types, representative of markedly different risk states. Classification of individuals by comparing office with either the 24 h or awake BP mean as �masked normotensives� (elevated clinic BP but normal ABPM), which should replace the terms of �isolated office� or �white-coat hypertension�, and �masked hypertensives� (normal clinic BP but elevated ABPM) is misleading and should be avoided because it disregards the clinical significance of the asleep BP mean. Outcome-based ABPM reference thresholds for men, which in the absence of compelling clinical conditions are 135/85 mmHg for the awake and 120/70 mmHg for the asleep SBP/DBP means, are lower by 10/5 mmHg for SBP/DBP in uncomplicated, low-CVD risk, women and lower by 15/10 mmHg for SBP/DBP in male and female high-risk patients, e.g., with diabetes, chronic kidney disease (CKD), and/or past CVD events. In the adult population, the combined prevalence of masked normotension and masked hypertension is >35%. Moreover, >20% of �normotensive� adults have a non-dipper BP profile and, thus, are at relatively high CVD risk. Clinic BP measurements, even if supplemented with home self-measurements, are unable to quantify 24 h BP patterning and asleep BP level, resulting in potential misclassification of up to 50% of all evaluated adults. ABPM should be viewed as the new gold standard to diagnose true hypertension, accurately assess consequent tissue/organ, maternal/fetal, and CVD risk, and individualize hypertension chronotherapy. ABPM should be a priority for persons likely to have a blunted nighttime BP decline and elevated CVD risk, i.e., those who are elderly and obese, those with secondary or resistant hypertension, and those diagnosed with diabetes, CKD, metabolic syndrome, and sleep disorders.